The second European evidence-based Consensus on the diagnosis and management of Crohn's disease

Clinics and Research in Hepatology and Gastroenterology

Volumn 35, Issue 5, 2011, Pages 340-343

  Eugène, Claude ^a  

^a Clinique Saint Louis   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BUDESONIDE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ARTICLE; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE SEVERITY; DUODENUM DISEASE; ESOPHAGUS DISEASE; EVIDENCE BASED MEDICINE; HUMAN; NUTRITIONAL SUPPORT; RELAPSE;

EID: 79956370876     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2011.03.002     Document Type: Article

References (15)

1. Van Assche G., Dignass A., Panes J., Beaugerie L., Karagiannis J., Allez M., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohn's Colitis 2010, 4:7-27.
2. Dignass A., Van Assche G., Lindsay J.O., Lémann M., Söderholm J., Colombel J.F., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohn's Colitis 2010, 4:28-62.
3. Van Assche G., Dignass A., Reinisch W., van der Woude C.J., Sturm A., De Vos M., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations. J Crohn's Colitis 2010, 4:63-101.
4. Colombel J.F., Sandborn W.J., Reinisch W., Mantzaris G.J., Kornblut A., Rachmilewitz D., et al. Infliximab, azathioprine or combination therapy for Crohn's disease. New Engl J Med 2010, 362:1383-1395.
5. Beaugerie L., Seksik P., Nion-Larmurier I., Gendre J.P., Cosnes J. Predictors of Crohn's disease. Gastroenterology 2006, 130:650-656.
6. D'Haens G., Baert F., Van Assche G., Caenepeel P., Vergauwe P., Tuynman H., et al. Early combined immunosuppression or conventional management in patients with new diagnosed Crohn's disease: an open randomised trial. Lancet 2008, 371:660-667.
7. Melmed G.Y., Spiegel B.M., Bressler B., Cheifetz A.S., Devlin S.M., Harrell L.E., et al. The appropriatness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all. Clin Gastroenterol Hepatol 2010, 8:655-659.
8. Baert F., Moortgat L., Van Assche G., Caenepeel P., Vergauwe P., De Vos M., et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010, 138:463-468.
9. Pineton de Chambrun G., Peyrin-Biroulet L., Lémann M., Colombel J.F. Clinical implications of mucosal healing for the management of IBD. Nat Rev/Gastroenterol Hepatol 2010, 7:15-29.
10. D'Haens GR, Panaccione R, Higgins PDR, Vermeire S, Gassull M, Chowers Y, et al. The London Position Statement of the World Congress on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2010 Nov 2 (Epub ahead of print).
11. Sandborn W.J. State of the art: immunosuppression and biologic therapy. Dig Dis 2010, 28:536-542.
12. Sokol H., Seksik P., Carrat F., Nion-Larmurier I., Vienne A., Beaugerie L., et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010, 59:1363-1368.
13. Beaugerie L., Brousse N., Bouvier A.M., Colombel J.F., Lémann M., Cosnes J. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009, 374:1617-1625.
14. Colombel J.F., Loftus E.V., Treamine W.J., Egan L.J., Harmsen W.C., Schleck C.D., et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004, 126:19-31.
15. De Silva S., Devlin S., Panaccione R. Optimizing the safety of biologic therapy for IBD. Nat Rev/Gastroenterol Hepatol 2010, 7:93-101.